Roth Capital Downgrades Galectin Therapeutics (GALT) to Sell
Tweet
Share
E-mail
Get Alerts GALT Hot Sheet
Price: $3.51 --0%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Join SI Premium – FREE
Roth Capital downgraded Galectin Therapeutics (NASDAQ: GALT) from Buy to Sell with a price target of $0.75.
For an analyst ratings summary and ratings history on Galectin Therapeutics click here. For more ratings news on Galectin Therapeutics click here.
Shares of Galectin Therapeutics closed at $2.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Downgrades China Literature (772:HK) (CHLLF) to Neutral
- BNP Paribas Exane Downgrades Lanxess AG (LXS:GR) (LNXSF) to Underperform
- Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
